Axial spondyloarthritis (axSpA) is a chronic inflammatory disease primarily affecting the spine and sacroiliac joints, causing pain and reduced mobility. According to Abhijeet Danve et al., 2024, it accounts for around 0.9-1.4% of the United States population. The axial spondyloarthritis (axSpA) pipeline analysis by Expert Market Research highlights a growing portfolio of axSpA therapeutics driven by increasing disease awareness, improved diagnostic tools, and rising demand for biologics. The market is expected to grow steadily due to ongoing clinical trials and advancements in axial spondyloarthritis (axSpA) drugs. Companies are focusing on novel targets and personalized treatment approaches to meet the unmet needs in axSpA management.
Major companies involved in the axial spondyloarthritis (axSpA) pipeline analysis include Suzhou Suncadia Biopharmaceuticals Co., Ltd., Sinocelltech Ltd., and others.
Leading drugs currently in the pipeline include SHR-1314, SCT650C, 608, and others.
The drug pipeline for axial spondyloarthritis is expected to grow due to increasing clinical trials of IL-17 and JAK inhibitors and rising regulatory approvals for targeted biologics and biosimilars.
The Axial Spondyloarthritis (axSpA) Pipeline Analysis Report by Expert Market Research gives comprehensive insights into axial spondyloarthritis (axSpA) therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for axial spondyloarthritis (axSpA). The axial spondyloarthritis (axSpA) report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The axial spondyloarthritis (axSpA) pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with axial spondyloarthritis (axSpA) treatment guidelines to ensure optimal care practices.
The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to axial spondyloarthritis (axSpA).
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Axial spondyloarthritis (axSpA) is a chronic inflammatory disease that primarily affects the sacroiliac joints and spine, leading to persistent back pain, stiffness, and fatigue. It includes two forms, namely, ankylosing spondylitis (radiographic axSpA) and non-radiographic axSpA, which lacks visible structural damage on X-rays. The disease often begins in early adulthood and may be underdiagnosed due to subtle early symptoms.
Axial spondyloarthritis (axSpA) is treated using nonsteroidal anti-inflammatory drugs, biologics such as tumor necrosis factor or interleukin-17 inhibitors, and physical therapy to manage symptoms and slow disease progression. In June 2020, Eli Lilly’s Taltz® (ixekizumab) became the first interleukin-17A antagonist approved by the U.S. FDA to treat non-radiographic axial spondyloarthritis, marking a significant advancement in targeted biologic therapies.
According to Abhijeet Danve et al., 2024, axial spondyloarthritis (axSpA) affects approximately 0.9-1.4% of the United States population and 0.66-1.3% in the United Kingdom. However, diagnostic prevalence remains much lower at 0.2–0.7%, highlighting significant underdiagnosis. As per Blessing Eze et al., 2024, arthritis overall is projected to affect 78 million United States adults by 2040, driving increased demand for effective axSpA drug development.
This section of the report covers the analysis of axial spondyloarthritis (axSpA) drug candidates based on several segmentations, including:
By Phase
The pipeline assessment report covers 50+ drug analyses based on phase:
By Drug Class
The axial spondyloarthritis (axSpA) pipeline analysis report covers 50+ drug analyses based on drug classes:
By Route of Administration
The pipeline assessment report covers 50+ drug analyses based on the route of administration.
The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase II and III, with 31%, cover a major share of the total axial spondyloarthritis (axSpA) clinical trials. It is followed by phase IV at 28% and phase I. The strong presence of advanced-stage candidates highlights promising development progress, indicating potential near-term treatment breakthroughs that can significantly enhance therapeutic options in the axSpA market.
The drug molecule categories covered under the axial spondyloarthritis (axSpA) pipeline analysis include small molecules, monoclonal antibodies, biologics, RNA-based therapeutics, and peptides. The axial spondyloarthritis (axSpA) report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for axial spondyloarthritis (axSpA). Interleukin-17 (IL-17) inhibitors are gaining prominence in the axial spondyloarthritis treatment pipeline as targeted immunotherapies. For instance, secukinumab, an IL-17A inhibitor, is under evaluation as a first-line biologic in the AScalate trial. The study investigates its efficacy compared to standard-of-care approaches, aiming to improve disease control through a treat-to-target strategy.
The EMR report for the axial spondyloarthritis (axSpA) pipeline covers the profile of key companies involved in clinical trials and their drugs under development. It provides a detailed axial spondyloarthritis (axSpA) therapeutic assessment, analyzing the competitive dynamics of the clinical trial landscape. Below is the list of a few players involved in axial spondyloarthritis (axSpA) clinical trials:
This section covers the detailed analysis of each drug under multiple phases, including phase I, phase II, phase III, phase IV, and emerging drugs for axial spondyloarthritis (axSpA). It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of axial spondyloarthritis (axSpA) drug candidates.
SHR-1314 injection, sponsored by Suzhou Suncadia Biopharmaceuticals Co., Ltd., is currently undergoing a Phase III trial to assess its efficacy and safety in adults with active non-radiographic axial spondyloarthritis. SHR-1314 (Vunakizumab) is a humanized IgG1/κ monoclonal antibody targeting IL-17A. This phase aims to confirm its clinical benefit by reducing inflammation and improving symptoms.
Sinocelltech Ltd. Is developing SCT650C, a novel humanized monoclonal antibody targeting IL-17A to treat axial spondyloarthritis (axSpA). In this ongoing Phase II, randomized, double-blinded study, researchers are evaluating its efficacy, safety, pharmacokinetics, and immunogenicity when administered subcutaneously. The trial has enrolled 168 participants to determine SCT650C’s therapeutic potential in controlling axSpA inflammation and symptoms.
SSGJ-608, a humanized monoclonal antibody targeting IL-17A, is currently being evaluated by Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. in a Phase II trial for non-radiographic axial spondyloarthritis (nr-axSpA). This study aims to assess the efficacy, safety, and tolerability of SSGJ-608 compared to placebo in patients with nr-axSpA.
*Please note that this is only a partial list; the complete list of drugs will be available in the full report.*
The Axial Spondyloarthritis (axSpA) Pipeline Analysis Report provides a strategic overview of the latest and future landscape of treatments for axial spondyloarthritis (axSpA). It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into Axial Spondyloarthritis (axSpA) collaborations, regulatory environments, and potential growth opportunities.
Axial Spondyloarthritis (axSpA) Epidemiology Forecast
Non-Radiographic Axial Spondyloarthritis (nr-AxSpA) Epidemiology Forecast
Upto 15% Off
USD
$1999 $1799
$3099 $2789
$4599 $3909
$5999 $5099
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
|
Scope of the Report |
Details |
|
Drug Pipeline by Clinical Trial Phase |
|
|
Route of Administration |
|
|
Drug Classes |
|
|
Leading Sponsors Covered |
|
|
Geographies Covered |
|
Mini Report
One User
USD 1,999
USD 1,799
tax inclusive*
Single User License
One User
USD 3,099
USD 2,789
tax inclusive*
Five User License
Five User
USD 4,599
USD 3,909
tax inclusive*
Corporate License
Unlimited Users
USD 5,999
USD 5,099
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Share